EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials

George N Okoli, Nicole Askin, Rasheda Rabbani

Clinical Drug Investigation · 2026-01 · 46 (1) · 37-48

DOI: 10.1007/s40261-025-01504-0 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, online erschienen am 25.11.2025. Verfasst von George N Okoli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Max Rady College of Medicine, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada. George.Okoli@umanitoba.ca. Hauptthemen laut MEDLINE: Hydroxylamines, Cytidine, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The evidence on molnupiravir for the treatment of adults with nonsevere coronavirus disease 2019 (COVID-19) remains underexplored. We conducted a systematic review with meta-analysis and trial sequential analysis (TSA) of clinically relevant outcomes from randomized controlled trials (RCTs) of molnupiravir for treatment of nonsevere COVID-19 in adults. METHODS: We searched for publications of RCTs of molnupiravir for nonsevere COVID-19 in appropriate bibliographic databases up to 1 February 2025. We pooled appropriate data utilizing an inverse variance, random-effects model, with results expressed as relative risk (RR) with associated 95% confidence intervals (CIs), and statistical heterogeneity between pooled estimates calculated using the I2 statistic. We appropriately conducted risk of bias assessment for the included RCTs and graded the quality of pooled evidence for each outcome using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. RESULTS: Out of 680 screened literature citations, nine RCTs involving a total of 30,971 patients met the eligibility criteria for inclusion in this review. The majority (78%) of these RCTs were of a low risk of bias. We determined that there was more viral clearance with molnupiravir treatment compared with placebo or no treatment (RR 1.08 [95% CI 1.01-1.16], I2 40.8%, five RCTs, 1785 patients, moderate quality evidence) and that treatment with molnupiravir did not reduce the risk of hospitalization (RR 0.73 [95% CI 0.47-1.14], I2 58.3%, five RCTs, 28,626 patients; high quality evidence), and all-cause mortality (RR 0.51 [95% CI 0.15-1.69], I2 36.8%, four RCTs, 27,445 patients; high quality evidence). We also determined that molnupiravir did not increase adverse or serious adverse reactions. However, TSA suggested more RCTs should be conducted before any conclusions can be reached for viral clearance, all-cause mortality, and adverse reactions, but that further RCTs on the risk of hospitalization and serious adverse reactions may not be needed. DISCUSSION: Notwithstanding a paucity of RCTs, our findings suggest that molnupiravir may only be efficacious for clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; the virus responsible for COVID-19) in adults with nonsevere COVID-19 although the evidence is not sufficient for conclusions to be drawn. More high quality RCTs are needed for a stronger evidence base.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxylaminesCytidineAntiviral AgentsCOVID-19 Drug TreatmentHumansRandomized Controlled Trials as TopicCOVID-19SARS-CoV-2

Substanzen

molnupiravirHydroxylaminesCytidineAntiviral Agents

Autor:innen und Institutionen

  • Max Rady College of Medicine, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada. George.Okoli@umanitoba.ca.
  • Neil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, MB, Canada.
  • Max Rady College of Medicine, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB, R3E 0T6, Canada.

Zitieren

APA

Okoli, G. N., Askin, N., & Rabbani, R. (2026). Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials. Clinical Drug Investigation, 46(1), 37-48. https://doi.org/10.1007/s40261-025-01504-0

Vancouver

Okoli GN, Askin N, Rabbani R. Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials. Clinical Drug Investigation. 2026;46(1):37-48. doi:10.1007/s40261-025-01504-0

BibTeX
@article{Okoli2026,
  author = {Okoli, George N and Askin, Nicole and Rabbani, Rasheda},
  title = {Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {1},
  pages = {37--48},
  doi = {10.1007/s40261-025-01504-0}
}
Kostenlos starten →